Literature DB >> 12056921

Patients' subjective experiences of antipsychotics: clinical relevance.

Jonathan S E Hellewell1.   

Abstract

The subjective experience of patients with schizophrenia who are receiving antipsychotic medication has been a neglected research area, as has the satisfaction of patients with their drug treatments. This is unfortunate, as satisfaction with treatment appears to be related strongly to the readiness of patients to take their medication as prescribed, and thereby to outcome. Patients' perceptions of their treatment do not appear to be related strongly to severity of illness or symptom ratings, although there are associations between perceptions of treatment and adverse effects. Surveys of patient experience with typical antipsychotics have tended to indicate high levels of dissatisfaction and perceived adverse effects. There have been a number of surveys of patients' perceptions of treatment with the atypical antipsychotics. These tend to accord with the expectation that a relative freedom from adverse effects with the atypical antipsychotics will be reflected in enhanced levels of satisfaction and perceived well-being. In general, these studies share a number of weaknesses, including small sample sizes, bias in selection of respondents, open treatment and lack of suitable comparator groups. In addition, many have adopted a cross-sectional, rather than longitudinal, approach and have relied on nonvalidated and perhaps idiosyncratic rating measures. Recently, there have been studies of better methodological quality. These, too, have indicated that patients regard the newer treatments more positively than the older regimens. In addition, there is now evidence that the various new-generation antipsychotics may be evaluated differently by patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056921     DOI: 10.2165/00023210-200216070-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  48 in total

1.  The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale.

Authors:  R M Norman; A K Malla; T McLean; L P Voruganti; L Cortese; E McIntosh; S Cheng; A Rickwood
Journal:  Acta Psychiatr Scand       Date:  2000-10       Impact factor: 6.392

2.  Intervention research in psychosis: issues related to the assessment of quality of life.

Authors:  A G Awad; L N Voruganti
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

3.  Differences in health values among patients, family members, and providers for outcomes in schizophrenia.

Authors:  L A Lenert; J Ziegler; T Lee; R Sommi; R Mahmoud
Journal:  Med Care       Date:  2000-10       Impact factor: 2.983

4.  Subjective experience and mental side-effects of antipsychotic treatment.

Authors:  J Gerlach; E B Larsen
Journal:  Acta Psychiatr Scand Suppl       Date:  1999

5.  Quality of life of seriously mentally ill persons in Mississippi.

Authors:  G Sullivan; K B Wells; B Leake
Journal:  Hosp Community Psychiatry       Date:  1991-07

6.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

Review 7.  Measures of quality of life among persons with severe and persistent mental disorders.

Authors:  A F Lehman
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1996-03       Impact factor: 4.328

8.  Methodologic standards for treatment outcome research in schizophrenia.

Authors:  W T Carpenter; D W Heinrichs; T E Hanlon
Journal:  Am J Psychiatry       Date:  1981-04       Impact factor: 18.112

9.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

Authors:  L Voruganti; L Cortese; L Oyewumi; Z Cernovsky; S Zirul; A Awad
Journal:  Schizophr Res       Date:  2000-06-16       Impact factor: 4.939

Review 10.  The content and context of compliance.

Authors:  P E Bebbington
Journal:  Int Clin Psychopharmacol       Date:  1995-01       Impact factor: 1.659

View more
  11 in total

1.  Effects of a Psychoeducation Program for People with Schizophrenia Aimed at Increasing Subjective Well-Being and the Factors Influencing Those Effects: a Preliminary Study.

Authors:  Ayumi Shinozaki; Teruo Hayashi; Hitoshi Okamura
Journal:  Psychiatr Q       Date:  2020-03

2.  Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.

Authors:  Naoaki Kuroda; Shiyou Sun; Chih-Kuang Lin; Nobuaki Morita; Hirotaka Kashiwase; Fude Yang; Yoji Nakatani
Journal:  Environ Health Prev Med       Date:  2008-08-12       Impact factor: 3.674

3.  An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service.

Authors:  Inti Qurashi; Paul Stephenson; Simon Chu; Chris Duffy; Nusrat Husain; Imran Chaudhry
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

Review 4.  The generic alternative in schizophrenia: opportunity or threat?

Authors:  Philippe Nuss; David Taylor; Marc De Hert; Martina Hummer
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Quetiapine. A review of its use in the management of schizophrenia.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  The impact of subjective well-being under neuroleptic treatment on compliance and remission.

Authors:  Walter de Millas; Martin Lambert; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

7.  Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.

Authors:  George Awad; Daisy Ng-Mak; Krithika Rajagopalan; Jay Hsu; Andrei Pikalov; Antony Loebel
Journal:  BMC Psychiatry       Date:  2016-06-01       Impact factor: 3.630

Review 8.  Patient and family attitudes toward schizophrenia treatment.

Authors:  Farzin Irani; Mary Dankert; Steven J Siegel
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

9.  Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20).

Authors:  Melina Siamouli; Katerina Moutou; Eleonora Pantoula; Stamatia Magiria; Irini Chatzivasileiou; Konstantinos Arapidis; Achileas Chatzivasileiou; Simeon Deres; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2009-01-21       Impact factor: 3.455

10.  Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Authors:  George Awad; Mariam Hassan; Antony Loebel; Jay Hsu; Andrei Pikalov; Krithika Rajagopalan
Journal:  BMC Psychiatry       Date:  2014-02-23       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.